BioNTech, DualityBio tout ‘clinically meaningful’ efficacy for ADC in mid-stage endometrial cancer trial

By /

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.

Scroll to Top